EICHOR
● Completed
A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults
Condition: Advanced Renal Cell Carcinoma · Sponsor: Ipsen
About this study
The purpose of this study is to collect data to describe the safety and effectiveness of cabozantinib and nivolumab in combination as a first-line treatment in adults with aRCC with clear cell-component, according to real-world clinical practice. The decision to prescribe cabozantinib and nivolumab in combination will be made prior to, and independently from, the decision to enrol the participant in study.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (66)
| CHU St Pierre & Brugmann | Brussels, Belgium | — |
| Jessa Ziekenhuis | Hasselt, Belgium | — |
| CHU Namur Mont-Godinne | Yvoir, Belgium | — |
| Centre Hospitalier Universitaire (CHU) de Angers | Angers, France | — |
| Hopital de Mercy- CHR Metz Thionville | Ars-Laquenexy, France | — |
| Institut Ste Catherine - Institut du Cancer Avignon Provence | Avignon, France | — |
| Centre Hospitalier Régional Universitaire de Besançon - Jean Minjoz | Besançon, France | — |
| ICONE | Bezannes, France | — |
| Groupe Hospitalier Saint-André (Bordeaux) | Bordeaux, France | — |
| Institut Bergonié | Bordeaux, France | — |
| Centre Hospitalier de Boulogne-sur-mer | Boulogne-sur-Mer, France | — |
| Centre Hospitalier Fleyriat | Bourg-en-Bresse, France | — |
+ 54 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05361434